Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04695015|
Recruitment Status : Not yet recruiting
First Posted : January 5, 2021
Last Update Posted : January 5, 2021
|Condition or disease|
|Melanoma (Skin) Melanoma in Situ Nevus Eye Sebaceous Gland Carcinoma of the Eyelid Basal Cell Carcinoma Squamous Cell Carcinoma in Situ Ocular Tumor|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm|
|Estimated Study Start Date :||December 31, 2020|
|Estimated Primary Completion Date :||June 1, 2022|
|Estimated Study Completion Date :||June 1, 2022|
Melanoma and Nevus
Patients diagnosed with melanoma or/and nevus on the skin around the eye before surgery.
Basal cell carcinoma;Squamous cell carcinoma;Sebaceous gland carcinoma
Patients diagnosed with basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma before surgery.
- To compare the diagnostic accuracy of OPAL and IHC for melanoma and other tumors. [ Time Frame: Up to 24 weeks. ]The result of OPAL automatic analysis will be compared with IHC manual counting analysis.The accuracy of the study will be declared "success" if OPAL automatic analysis meet more than 85% of the manual count for all antibody.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04695015
|Contact: Chun Zhang, MD/PHDfirstname.lastname@example.org|
|Contact: Defu Wu, email@example.com|
|Principal Investigator:||Chun Zhang, MD/PHD||Peking University Third Hospital|